OPEN END TURBO CALL WARRANT - ELI LILLY & CO | Real-time Bid/Ask 09:45:02 27/06/2024 BST | ||
| 3.28 CHF / 3.3 CHF | 0.00% |
|
| Current month | +29.02% | ||
| 1 month | +29.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 3.29 | -0.90% |
| 25/06/24 | 3.32 | +3.75% |
| 24/06/24 | 3.2 | +2.24% |
| 21/06/24 | 3.13 | -2.80% |
| 20/06/24 | 3.22 | +2.22% |
Delayed Quote Swiss Exchange
Last update June 26, 2024 at 04:20 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYDDU | |
| ISIN | CH1290916530 |
| Date issued | 22/09/2023 |
| Strike | 540 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.41 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.32 CHF |
|---|---|
| Lowest since issue | 0.17 CHF |
| Spread | 0.02 CHF |
| Spread % | 0.61% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- LLYDDU Certificat
